Previous close | 2.6700 |
Open | 2.6200 |
Bid | 2.6000 x 1100 |
Ask | 2.6100 x 1800 |
Day's range | 2.5800 - 2.6800 |
52-week range | 2.5800 - 112.8700 |
Volume | |
Avg. volume | 1,066,418 |
Market cap | 142.968M |
Beta (5Y monthly) | 0.94 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atopic dermatitis i
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Recent Events Initiated a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe
– Management will discuss lirentelimab development and Allakos pipeline – REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company” or “Allakos”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today announced that it will host an Investor Day on February 15th starting at 8:00 am ET. Members of Allakos’ management team will be joined by prominent clinical leaders to discuss data from